Comparison of treatment outcomes of endoscope-guided pneumatic dilation and laparoscopic Heller myotomy  by Wang, Hsin-Ming et al.
Kaohsiung Journal of Medical Sciences (2015) 31, 639e643Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /www.kjms-onl ine.comORIGINAL ARTICLEComparison of treatment outcomes of
endoscope-guided pneumatic dilation and
laparoscopic Heller myotomy
Hsin-Ming Wang a, Wei-Chen Tai a, Seng-Kee Chuah a,*, Hung-I Lu b,
Lung-Sheng Lu a, Chih-Ming Liang a, Chung-Huang Kuo a, Yi-Chun Chiu a,
Keng-Liang Wu a, Chi-Sin Changchien aa Division of Hepato-gastroenterology, Department of Internal Medicine, Kaohsiung Chang
Gung Memorial Hospital and Chang Gung University College of Medicine, Taiwan
b Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Kaohsiung Chang
Gung Memorial Hospital and Chang Gung University College of Medicine, TaiwanReceived 29 July 2015; accepted 1 October 2015
Available online 30 November 2015KEYWORDS
Clinical remission;
Endoscope-guided
pneumatic dilation;
Esophageal achalasia;
Laparoscopic Heller
myotomyConflicts of interest: All authors d
* Corresponding author. Division of
Hsiang, Kaohsiung County 833, Taiwan
E-mail address: chuahsk@seed.net
http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2015, KaohsiuAbstract The debate onwhich is the better choice between laparoscopic Hellermyotomy (LHM)
and endoscopic pneumatic dilation (PD) for esophageal achalasia has been ongoing for decades.
This study aims to compare the results of endoscope-guided PD and LHM in 42 patients with acha-
lasia betweenMay1996andAugust2011.Twenty-onepatientswhohad receivedPDand21whohad
received LHMwere enrolled. The cumulative remission rate was analyzed using the KaplaneMeier
methodwith theassessment of symptomscores betweengrades beforeandafterPDorLHMdoneat
6 weeks, 6months, 1 year, and then every year thereafter. Possible confounding factors related to
the remissions were analyzed by Cox’s proportional hazard model. For PD, the cumulative remis-
sion rates were 81.0% (1 year), 76.2% (2), 66.7% (3), 61.9% (4), and 47.6% (5). For LHM, the cumu-
lative remission rates were 90.5% every year from the 1st to the 5th. The LHM patients had
significantly better remission rates than the PD patients (pZ 0.033, by log-rank test). The LHM
group had a longer hospital stay than the PD group [median (interquartile range): 8 (6.5e10) days
vs. 3 (2e3) days, p < 0.001) and had more reflux complications (52.4% vs. 19.0%, pZ 0.024). No
perforation occurred in either group. In conclusion, the 5-year cumulative effectiveness of LHM
is better than that of PD despite the association of LHM with more reflux events (52.4%).
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.eclare no conflicts of interest.
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640 H.-M. Wang et al.IntroductionAchalasia is the primary motility dysfunction of the
esophagus with the selective loss of inhibitory neurons of
the myenteric plexus, which produces vasoactive intestinal
polypeptides, nitric oxide, and inflammatory infiltrates and
is thereby responsible for abnormal lower esophageal
sphincter (LES) dysfunction. This results in the unopposed
excitation of the LES and in the dysfunction or failure of the
LES to relax in response to each swallow [1e6]. Dysphagia
to both liquid and solid foods is the most commonly
encountered symptom.
The currently available therapeutic options aim at
loosening the LES and hence at relaxing it and relieving the
obstruction of the esophagus [3]. Laparoscopic Heller
myotomy (LHM) and pneumatic dilation (PD) are still the
key treatment options, despite the introduction of peroral
endoscopic myotomy (POEM) and laparoendoscopic single-
site Heller myotomy with anterior fundoplication. Adding
to the already ongoing debates on the superiority between
PD and LHM, the first multiple-center randomized
controlled 2-year follow-up research conducted by the
European Achalasia Trial group indicated that LHM is not
superior to PD [7]. However, publications on the satisfac-
tory long-term success of laparoscopic surgical outcomes
continue to emerge. Up to now, controversy surrounds the
choice of LHM as the primary treatment for achalasia or as
second-line treatment following failure of nonsurgical
intervention after so many decades of real-world practice.
This 5-year follow-up study aims to compare the results of
endoscope-guided PD and LHM.
Patients and methods
Patients
We reviewed the medical files of the hospital admissions of
patients with achalasia between May 1996 and August 2011.
The PD patients were enrolled from 1996 and followed up
until 2003, and the LHM patients were enrolled from 2006
and followed up until 2011. Twenty-one patients (12 men, 9
women) received LHM in the surgical unit, and 21 (13 men,
8 women) received endoscope-guided PD treatment in our
unit. We excluded all patients who had prior treatments
such as previous PD, botulinum toxin injection, and Heller
operation; patients with esophageal obstructions caused by
intrinsic or extrinsic events as determined by x-ray film
examination and endoscopy; and patients with episodes of
esophageal or gastric tumors, peptic stricture, prior surgi-
cal fundoplication, and incomplete chart recording. The
mean age was 43.4  17.78 years (range, 17 years to 78
years) in the LHM group and 49.9  20.2 years (range, 18
years to 93 years). All patients had dysphagia of both liquid
and solid foods; some had food regurgitation (92.8%), body
weight loss (61.9%), chest pains (38.1%), and aspiration
pneumonia (4.7%). The diagnosis was confirmed by one or
more of the following examinations: endoscopic examina-
tions, barium esophagography, and manometric study. We
performed endoscopic ultrasonography or computed to-
mography to rule out pseudoachalasia. We performed
endoscope-guided PD under conscious sedation (after thepatients fasted overnight) using a 3-cm-diameter Rigiflex
balloon dilator (Microvasive, Watertown, MA, USA).
Depending on the tolerance of the patient, the balloon was
inflated up to 10e12 pounds per square inch and main-
tained for 60 seconds, and the step is then repeated for
another 15e30 seconds. The patients ingested Gastrografin
after the dilation so that we could determine whether
esophageal perforation had taken place. LHM was per-
formed by experienced cardiacevascular surgeons in
Kaohsiung Chang Gung Memorial Hospital (KCGMH).
This retrospective chart review study was approved by
both the Institutional Review Board and the Ethics Com-
mittee of KCGMH, Taiwan (IRB102-2468B). Written
informed-consent forms were signed by subjects 18 years
and older or by parents or guardians for younger subjects
before they underwent endoscopic interventions.Barium esophagogram
A timed barium esophagogram was performed on the pa-
tients before and after PD and LHM at the initial investi-
gation, 6 weeks later, and every 1 year thereafter to
objectively assess improvement in esophageal emptying.Symptom score assessment
Symptom improvement status was determined using the
Eckardt symptom score [8] at the initial investigation, 6
weeks later, and every 1 year thereafter. Depending on
whether dysphagia, regurgitation, and chest pain occurred
occasionally, daily, or several times during the day, a
symptom score of 0 to 3 was determined. In addition, a
symptom score of 0 to 3 was assigned to the degree of
weight loss. Thus, a completely asymptomatic patient
would have a symptom score of 0, whereas a severely
affected patient could have a symptom score of up to 12.
Patients were considered to have reached clinical remission
if symptoms had totally disappeared or had improved by at
least 2 points and did not exceed a score of 3. Patients who
requested further therapy despite having a symptom score
of less than 4 were considered to have treatment failure.Statistical analysis
Statistical analysis was performed using the statistical
software SPSS 17.0 (SPSS Inc., Chicago, IL, USA). Numerical
data were compared using the ManneWhitney test. For
categorical data, the chi-square or Fisher’s exact test was
applied. The responses of both groups to the initial treat-
ment, such as their manometric results, were compared,
and their symptom scores were compared using the Man-
neWhitney test. In both arms, the cumulative remission
rate was analyzed using the KaplaneMeier method with
assessment of symptom scores between grades before and
after PD and LHM in every year thereafter, and differences
in curves between the two groups were statistically
compared by log-rank test. A value of p < 0.05 was
considered statistically significant.
Figure 1. Overall rates of LHM and PD remission during
5-year follow up. * p Z 0.033. LHM Z laparoscopic Heller
myotomy; PD Z pneumatic dilation.
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The baseline patient characteristics in the initial treatment
are shown in Table 1. Most patients suffered from severe
disease with high symptom scores of 6 or more when
referred. The mean LES pressure before PD was
40.3  14.3 mmHg (range, 18e78 mmHg) in the LHM group
and 34.1  13.3 mmHg (range, 21e60 mmHg) in the PD
group. The median (interquartile range, IQR) of the PD
group was 60 (30e77) months, and that of the LHM group
was 51 (20e71) months.
The median improved symptom score of the LHM group
was 4 (range, 3e5) at Week 6, 4 (4e5) at Year 1, 5 (4e6) at
Year 2, 5 (4e6) at Year 3, 6 (5e7) at Year 4, and 5 (5e7) at
Year 5. The same score of the PD group was 5 (4e6) at Week
6, 5 (5e6) at Year 1, 5 (2e7) at Year 2, 5 (3e7) at Year 3, 4
(2e7) at Year 4, and 4 (2e7) at Year 5. No significant dif-
ference was found between these two study groups at Week
6, Year 1, or Year 2. However, the PD group obtained lower
median improved scores than the LHM group at Year 3
(p Z 0.045), Year 4 (p < 0.001), and Year 5 (p Z 0.029).
The median body weight (BW) change in the LHM group
was 1.2 kg (range, 1e1.8) at Week 6, 2 kg (1.4e2.5) at Year
1, 2.2 kg (1.4e2.6) at Year 2, 3 kg (2.6e3) at Year 3, 3.3 kg
(3.1e3.6) at Year 4, and 3.8 kg (3.5e4.4) at Year 5. The
same change in the PD group was 1.5 kg (0.8e2) at Week 6,
2.1 kg (1.4e2.6) at Year 1, 2.4 kg (1.8e3.7) at Year 2, 3.1 kg
(1.8e3.8) at Year 3, 3.4 kg (2.1e4.0) at Year 4, and 3.9 kg
(2.5e4.1) at Year 5. No significant difference in BW change
was observed in these two groups.
The responses to the initial treatments in both groups
according to symptom score are shown in Figure 1. BothTable 1 Baseline patient characteristics based on initial
treatment and post-treatment.
Variables LHM PD p
Age (y), mean (SD) 43.4 (16.4) 49.9 (20.2) 0.314
Range 17e78 18e93
Age > 40 y, n (%) 12 (57.1) 15 (71.4) 0.334
Sex, n (%) 0.753
Male 12 (57.1) 13 (61.9)
Female 9 (42.9) 8 (38.1)
Symptom score, n (%) 0.001
4e5 10 (47.6) 0 (0)
6e7 6 (28.6) 12 (57.1)
8e9 5 (23.8) 9 (42.9)
LES pressure (mmHg),
mean (SD)
40.3 (14.3) 34.1 (13.3) 0.172
Range 18e78 21e60
Hospital stay (d),
mean (SD)
9.4 (5.3) 2.8 (0.6) <0.001
Range 4e27 2e4
Complications, n (%) 11 (52.4) 4 (19.0) 0.024
Perforation 0 (0) 0 (0) d
Reflux acid-P (GERD) 11 (52.4) 4 (19.0) 0.024
Bleeding 0 (0) 2 (9.5) 0.488
GERD Z gastroesophageal reflux disease; LES Z lower esoph-
ageal sphincter; LHM Z laparoscopic Heller myotomy;
PD Z pneumatic dilation; SD Z standard deviation.groups were followed up at regular intervals for a median of
4.62 years. For PD, the cumulative remission rates were 81%
(1 year), 76.2% (2 years), 66.7% (3 years), 61.9% (4 years),
and 47.6% (5 years). For LHM, the same rates were 90.5%
every year for the 1st to 5th years. The LHM patients had
significantly better remission rates than the PD patients
(p Z 0.033, by log-rank test). The LHM group had a longer
hospital stay than the PD group [median (IQR)Z 8 (6.5e10)
days vs. 3 (2e3) days, p < 0.001] and more reflux compli-
cations (52.4% vs. 19.0%, p Z 0.024). Nine patients were
available for follow up at the 5th year in the PD group and
six patients in the LHM group.
Relapse occurred in 11 patients in the PD group during
the follow-up period. Four experienced only chest pain
and/or very mild dysphagia and needed no further treat-
ment. Seven suffered from recurrent symptoms of
dysphagia that affected their quality of life. Two received a
second PD, which was successful. Four patients chose sur-
gery, and one refused further treatment. Cox’s propor-
tional hazard model was used to analyze the risk factors
associated with treatment failure (relapse), and the result
showed that age, symptom score, sex, post-treatment
complications, and hospitalization period were not rele-
vant to clinical remission. However, the treatment choice
for achalasia was a possible risk factor of treatment failure
(PD vs. LHM, hazard ratio: 4.36, p Z 0.057) (Table 2).
Four patients (21.9%) had complications after the initial
PD.Twohadaminorbleeding event, but they recoveredafter
medical treatment. These patients had stable vital signs and
hemoglobin levels still within normal limits. Both patients
and two others suffered from mild symptomatic reflux
esophagitis. All four of them achieved remissionwith proton-
pump inhibitor (PPI) therapy once daily for 4e8weeks. In the
LHM group, as high as 54% had reflux events, compared with
the 19% of the PD group (pZ 0.024). No perforation occurred
in either group. All of these patients survived.Discussion
Our results showed that the cumulative remission rates
were better in the LHM patients, especially at Year 5
Table 2 Univariate and multivariate analyses of risk factors associated with treatment failure.
Factors Comparisons Univariate Multivariate
HR (95% CI) p HR (95% CI) p
Treatment PD vs. LHM 4.36 (0.96e19.80) 0.057 4.36 (0.96e19.80) 0.057
Sex F vs. M 1.02 (0.33e3.15) 0.968 d d
Age (y) <40 vs. >40 2.35 (0.77e7.13) 0.131 d d
Symptom score 8e9 vs. 4e7 1.61 (0.54e4.79) 0.395 d d
LES pressure (mmHg) <30 vs. 30 2.33 (0.71e7.65) 0.162 d d
Complications yes vs. no 0.97 (0.30e3.15) 0.957 d d
Hospital stay (d) per 1 d increase 0.80 (0.62e1.04) 0.100 d d
CIZ confidence interval; HRZ hazard ratio; LESZ lower esophageal sphincter; LHMZ laparoscopic Heller myotomy; PDZ pneumatic
dilation.
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However, the LHM group suffered from more reflux com-
plications than the PD group.
Controversy surrounds the choice of LHM as the primary
treatment for achalasia or as second-line treatment
following failure of nonsurgical intervention after so many
decades in real-world practice. Some surgeons heuristically
believe that LHM is more technically difficult following PD,
but others claim that PD does not hinder future myotomy
[9]. While the debate on which technique is superior con-
tinues, the first randomized controlled trial comparing LHM
and PD, conducted by the European Achalasia Trial group,
suggested that after 2 years of follow up, LHM, compared
with PD, is not associated with superior rates of therapeutic
success [7]. Those who favor PD believe that PD and LHM
are equally efficient. However, the follow-up duration of
that study was not long enough for a conclusion to declare
equality between the two.
In the current study, the balloon used for dilation was only
30 mm. Graded balloon dilation starting with a 3 cm Rigiflex
balloon as the initial dilator and progressing to 3.5 and 4 cm
balloons in the absence of a response to the previous balloon
size seems to be the safest approach for successful PD [10]. A
review of 21 studies using Rigiflex balloons demonstrated
that the initial success rate depends on balloon size, with
larger balloons showing better outcomes. Success rates of
74%, 80%, and 90% were achieved when 30 mm, 35 mm, and
40 mm balloons, respectively, were used [11].
Complications and the long-term effectiveness of the
procedure are the main concerns in the decision making for
treatment choice. In this study, more complications
occurred in the surgical group than in the PD group, but
only because as high as 54% of the LHM group had reflux
events, compared with 19% of the PD group (p Z 0.024).
This has been the main drawback of LHM as abnormal acid
exposure after surgery could be long lasting despite partial
fundoplication. Fortunately, all reflux events in both groups
could be controlled by PPIs. Generally, the prevalence of
reflux symptoms is low, so only a minority of patients need
long-term PPIs [12e14]. However, although reflux can
usually be overcome by such inhibitors, the risk of its long-
term complications (albeit rarely occurring), such as stric-
ture, Barrett’s esophagus, and adenocarcinoma, should be
taken into account. In contrast, reflux symptoms in post-PD
patients are usually mild and transient. They can easily be
controlled by a short course of PPI treatment. The mostsevere complication of PD is perforation, which occurs in
approximately 1e2% of patients. Such perforation is usually
minor but can be dangerous if ignored [15,16]. No perfo-
ration was found in the current study. Furthermore, acha-
lasia patients are at risk of esophageal cancer, although the
reported incidence rates of carcinoma in these patients are
relatively low [17]. Bru¨cher et al. [18] found that in pa-
tients with long-standing achalasia, the risk for developing
esophageal cancer is about 140 times that of the general
population. In the current study, no esophageal cancer was
reported during the follow-up period.
In terms of 5-year effectiveness, LHM was superior
(90.5% remission rate at Year 5 vs. 47.6% in the PD group).
Thus far, LHM is still generally considered to be superior to
PD in treating achalasia and is regarded the first choice of
treatment for the condition. LHM is usually suggested for
young patients (<40e45 years), male patients, patients
with pulmonary symptoms, and patients with failed
response to one or two initial dilations [1,19,20].
The novel endoscopic esophagomyotomy for achalasia,
POEM, can accomplish longer myotomy. This is a remark-
able advancement because it was difficult for surgeons to
extend the length of myotomy to the thoracic esophagus,
especially with advanced disease or severe fibrosis. Studies
on this technique have obtained good short-term results
without serious complications, but long-term follow-up
results are necessary [21e25]. Moreover, POEM can be a
challenging and demanding technique even for experienced
endoscopists. It can be hazardous in case of complicated
purulent mediastinitis. Validations with long-term effec-
tiveness and safety reports could be another breakthrough
in the treatment of esophageal achalasia. Long-term follow
up with POEM to test long-term effectiveness and the
cautious monitoring of safety issues are important.
Our study has potential limitations. This is a single-
center report, and the small sample size, nonrandom
sampling, and different study periods could have resulted
in selection bias. Caution must be taken in extrapolating
the results. Besides, this is a retrospective chart review
study with observations based on hospitalized patients with
a diagnosis of achalasia. Prospective multicenter data with
a larger sample size would be more convincing.
Second, the PD patients had no symptom scores less than
5d which is a limitation because their pretreatment scores
were higher. Finally, the follow-up rate decreased after the
4th year.
Pneumatic dilation and Heller myotomy for achalasia 643In conclusion, this study shows that the 5-year cumula-
tive effectiveness of LHM is better than that of PD despite
LHM’s association with more reflux events (52.4%).Acknowledgments
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